TY - JOUR
T1 - Control of glycolytic flux by AMP-activated protein kinase in tumor cells adapted to low ph1
AU - Mendoza, Erin E.
AU - Pocceschi, Michael G.
AU - Kong, Xiangul
AU - Leeper, Dennis B.
AU - Caro, Jaime
AU - Limesand, Kirsten H.
AU - Burd, Randy
N1 - Funding Information:
Address all correspondence to: Randy Burd, PhD, Department of Nutritional Sciences, University of Arizona, Shantz Bldg, Room 301, 1177 E 4th St, Tucson, AZ 85721. E-mail: rburd@u.arizona.edu 1This work was funded in part by grant 1R21CA139183-01A2 (R.B.). Received 28 October 2011; Revised 10 March 2012; Accepted 12 March 2012 Copyright © 2012 Neoplasia Press, Inc. Open access under CC BY-NC-ND license. 1944-7124/12 DOI 10.1593/tlo.11319
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2012/6
Y1 - 2012/6
N2 - Tumor cells grow in nutrient- and oxygen-deprived microenvironments and adapt to the suboptimal growth conditions by altering their metabolic pathways. This adaptation process commonly results in a tumor phenotype that displays a high rate of aerobic glycolysis and aggressive tumor characteristics. The glucose regulatory molecule, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), is a bifunctional enzyme that is central to glycolytic flux and is downstream of the metabolic stress sensor AMP-activated protein kinase (AMPK), which has been suggested to modulate glycolysis and possibly activate isoforms of PFKFB, specifically PFKFB3 expressed in tumor cells. Our results demonstrated that long-term low pH exposure induced AMPK activation, which resulted in the up-regulation of PFKFB3 and an increase in its serine residue phosphorylation. Pharmacologic activation of AMPK resulted in an increase in PFKFB3 as well as an increase in glucose consumption, whereas in contrast, inhibition of AMPK resulted in the down-regulation of PFKFB3 and decreased glycolysis. PFKFB3 overexpression in DB-1 tumor cells induced a high rate of glycolysis and inhibited oxygen consumption, confirming its role in controlling glycolytic flux. These results show that low pH is a physiological stress that can promote a glycolytic phenotype commonly associated with tumorigenesis. The implications are that the tumor microenviroment contributes to tumor growth and treatment resistance.
AB - Tumor cells grow in nutrient- and oxygen-deprived microenvironments and adapt to the suboptimal growth conditions by altering their metabolic pathways. This adaptation process commonly results in a tumor phenotype that displays a high rate of aerobic glycolysis and aggressive tumor characteristics. The glucose regulatory molecule, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), is a bifunctional enzyme that is central to glycolytic flux and is downstream of the metabolic stress sensor AMP-activated protein kinase (AMPK), which has been suggested to modulate glycolysis and possibly activate isoforms of PFKFB, specifically PFKFB3 expressed in tumor cells. Our results demonstrated that long-term low pH exposure induced AMPK activation, which resulted in the up-regulation of PFKFB3 and an increase in its serine residue phosphorylation. Pharmacologic activation of AMPK resulted in an increase in PFKFB3 as well as an increase in glucose consumption, whereas in contrast, inhibition of AMPK resulted in the down-regulation of PFKFB3 and decreased glycolysis. PFKFB3 overexpression in DB-1 tumor cells induced a high rate of glycolysis and inhibited oxygen consumption, confirming its role in controlling glycolytic flux. These results show that low pH is a physiological stress that can promote a glycolytic phenotype commonly associated with tumorigenesis. The implications are that the tumor microenviroment contributes to tumor growth and treatment resistance.
UR - http://www.scopus.com/inward/record.url?scp=84862023083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862023083&partnerID=8YFLogxK
U2 - 10.1593/tlo.11319
DO - 10.1593/tlo.11319
M3 - Article
AN - SCOPUS:84862023083
VL - 5
SP - 208
EP - 216
JO - Translational Oncology
JF - Translational Oncology
SN - 1936-5233
IS - 3
ER -